{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Sanofi LPS18183: A single-arm, open-label, Phase 2 study evaluating subcutaneous administration of isatuximab, administered by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma (RRMM).","item":"https:\/\/www.regionalcancercare.org\/trials\/sanofi-lps18183-a-single-arm-open-label-phase-2-study-evaluating-subcutaneous-administration-of-isatuximab-administered-by-an-on-body-delivery-system-in-combination-with-weekly-carfilzomib-and-de\/#breadcrumbitem"}]}